Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Chief Medical Officer | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,038 |
Ending reported balance
After 2026-05-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-20 · Exercise / conversion · Acquired 9,450 · Balance 44,731 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 28,350 restricted stock units was as follows: 9,450 shares vested on May 20, 2026; 9,450 shares will vest on May 20, 2027; 9,450 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Row 2 · 2026-05-20 · Tax withholding · Disposed 2,693 · Balance 42,038 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 18,900 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Exercise / conversion · Disposed 9,450 · Balance 18,900 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 28,350 restricted stock units was as follows: 9,450 shares vested on May 20, 2026; 9,450 shares will vest on May 20, 2027; 9,450 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 37,684 |
Reported balance
After 2026-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-20 · Grant · Acquired 37,684 · Balance 37,684 F5: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 12,562 shares will vest on February 26, 2027; 12,561 shares will vest on February 26, 2028; 12,561 and shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. |
| Common Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2036-05-20 | Direct | 46,876 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Grant · Acquired 46,876 · Balance 46,876 F3: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. F4: The vesting schedule for the options granted on May 20, 2026 was as follows: 15,626 shares will vest on February 26, 2027; 15,625 shares will vest on February 26, 2028; 15,625 shares will vest on February 26, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 28,350 restricted stock units was as follows: 9,450 shares vested on May 20, 2026; 9,450 shares will vest on May 20, 2027; 9,450 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
F3: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
F4: The vesting schedule for the options granted on May 20, 2026 was as follows: 15,626 shares will vest on February 26, 2027; 15,625 shares will vest on February 26, 2028; 15,625 shares will vest on February 26, 2029.
F5: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 12,562 shares will vest on February 26, 2027; 12,561 shares will vest on February 26, 2028; 12,561 and shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F6: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 21, 2026 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 37,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001936799-26-000006 · wk-form4_1779393902.xml · derivative · entry 5 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,684 Underlying: Common Stock · 37,684 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 12,562 shares will vest on February 26, 2027; 12,561 shares will vest on February 26, 2028; 12,561 and shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6 · date: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 12,562 shares will vest on February 26, 2027; 12,561 shares will vest on February 26, 2028; 12,561 and shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 12,562 shares will vest on February 26, 2027; 12,561 shares will vest on February 26, 2028; 12,561 and shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 46,876 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001936799-26-000006 · wk-form4_1779393902.xml · derivative · entry 4 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,876 Underlying: Common Stock · 46,876 shares Expires 2036-05-20 F3 · date: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. F4 · derivative.exercise_date: The vesting schedule for the options granted on May 20, 2026 was as follows: 15,626 shares will vest on February 26, 2027; 15,625 shares will vest on February 26, 2028; 15,625 shares will vest on February 26, 2029. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 9,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001936799-26-000006 · wk-form4_1779393902.xml · derivative · entry 3 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,900 Underlying: Common Stock · 9,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 28,350 restricted stock units was as follows: 9,450 shares vested on May 20, 2026; 9,450 shares will vest on May 20, 2027; 9,450 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 28,350 restricted stock units was as follows: 9,450 shares vested on May 20, 2026; 9,450 shares will vest on May 20, 2027; 9,450 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 28,350 restricted stock units was as follows: 9,450 shares vested on May 20, 2026; 9,450 shares will vest on May 20, 2027; 9,450 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 2,693 | $1.23 | $3,312.39 |
DisclosureSEC source: 0001936799-26-000006 · wk-form4_1779393902.xml · nonDerivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,038 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 9,450 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001936799-26-000006 · wk-form4_1779393902.xml · nonDerivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 28,350 restricted stock units was as follows: 9,450 shares vested on May 20, 2026; 9,450 shares will vest on May 20, 2027; 9,450 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001936799-26-000005 · wk-form4_1779134693.xml · derivative · entry 3 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,385 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units was as follows: 2,386 shares vested on May 15, 2024; 2,385 shares vested on May 15, 2025; and 2,385 shares vested on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units was as follows: 2,386 shares vested on May 15, 2024; 2,385 shares vested on May 15, 2025; and 2,385 shares vested on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units was as follows: 2,386 shares vested on May 15, 2024; 2,385 shares vested on May 15, 2025; and 2,385 shares vested on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 680 | $1.30 | $884.00 |
DisclosureSEC source: 0001936799-26-000005 · wk-form4_1779134693.xml · nonDerivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,281 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,385 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001936799-26-000005 · wk-form4_1779134693.xml · nonDerivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units was as follows: 2,386 shares vested on May 15, 2024; 2,385 shares vested on May 15, 2025; and 2,385 shares vested on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 4,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001936799-26-000004 · wk-form4_1775077509.xml · derivative · entry 3 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,292 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on March 31, 2026. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on March 31, 2026. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 1,223 | $1.74 | $2,128.02 |
DisclosureSEC source: 0001936799-26-000004 · wk-form4_1775077509.xml · nonDerivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,576 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 4,292 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001936799-26-000004 · wk-form4_1775077509.xml · nonDerivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on March 31, 2026. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:54 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 29,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001936799-26-000003 · wk-form4_1772747679.xml · derivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,608 Underlying: Common Stock · 29,608 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 29,608 restricted stock units granted on March 4, 2026 was as follows: 9,870 shares will vest on February 26, 2027; 9,869 shares will vest on February 26, 2028; and 9,869 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 29,608 restricted stock units granted on March 4, 2026 was as follows: 9,870 shares will vest on February 26, 2027; 9,869 shares will vest on February 26, 2028; and 9,869 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 29,608 restricted stock units granted on March 4, 2026 was as follows: 9,870 shares will vest on February 26, 2027; 9,869 shares will vest on February 26, 2028; and 9,869 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:54 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 36,832 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001936799-26-000003 · wk-form4_1772747679.xml · derivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,832 Underlying: Common Stock · 36,832 shares Expires 2036-02-26 F1 · derivative.exercise_date: The vesting schedule for the 36,832 options granted on March 4, 2026 was as follows: 12,278 shares will vest on February 26, 2027; 12,277 shares will vest on February 26, 2028; 12,277 shares will vest on February 26, 2029. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:47 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001936799-26-000002 · wk-form4_1772228830.xml · derivative · entry 5 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,100 Underlying: Common Stock · 11,550 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 34,650 restricted stock units granted on February 27, 2025 was as follows: 11,550 shares vested on February 26, 2026; 11,550 shares will vest on February 26, 2027; 11,550 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 34,650 restricted stock units granted on February 27, 2025 was as follows: 11,550 shares vested on February 26, 2026; 11,550 shares will vest on February 26, 2027; 11,550 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 34,650 restricted stock units granted on February 27, 2025 was as follows: 11,550 shares vested on February 26, 2026; 11,550 shares will vest on February 26, 2027; 11,550 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:47 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 5,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001936799-26-000002 · wk-form4_1772228830.xml · derivative · entry 4 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,009 Underlying: Common Stock · 5,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 was as follows: 5,010 shares vested on February 26, 2025; 5,010 shares vested on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 was as follows: 5,010 shares vested on February 26, 2025; 5,010 shares vested on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 was as follows: 5,010 shares vested on February 26, 2025; 5,010 shares vested on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:47 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 3,903 | $1.79 | $6,986.37 |
DisclosureSEC source: 0001936799-26-000002 · wk-form4_1772228830.xml · nonDerivative · entry 3 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,507 F3 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (2) herein. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:47 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,550 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001936799-26-000002 · wk-form4_1772228830.xml · nonDerivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 34,650 restricted stock units granted on February 27, 2025 was as follows: 11,550 shares vested on February 26, 2026; 11,550 shares will vest on February 26, 2027; 11,550 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:47 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 5,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001936799-26-000002 · wk-form4_1772228830.xml · nonDerivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 was as follows: 5,010 shares vested on February 26, 2025; 5,010 shares vested on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,916 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000046 · wk-form4_1751400477.xml · derivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,916 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 8,749 restricted stock units was as follows: 2,916 shares vested on June 30, 2023; 2,917 shares vested on June 30, 2024; and 2,916 shares vested on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 8,749 restricted stock units was as follows: 2,916 shares vested on June 30, 2023; 2,917 shares vested on June 30, 2024; and 2,916 shares vested on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 8,749 restricted stock units was as follows: 2,916 shares vested on June 30, 2023; 2,917 shares vested on June 30, 2024; and 2,916 shares vested on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,916 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000046 · wk-form4_1751400477.xml · nonDerivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 8,749 restricted stock units was as follows: 2,916 shares vested on June 30, 2023; 2,917 shares vested on June 30, 2024; and 2,916 shares vested on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 20, 2025 Filed May 21, 2025 20:57 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 35,100 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001055726-25-000033 · wk-form4_1747861034.xml · derivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,100 Underlying: Common Stock · 35,100 shares Expires 2035-05-20 F2 · derivative.exercise_date: The vesting schedule for the 31,500 options is as follows: 17,550 shares will vest on May 20, 2027 and 17,550 shares will vest on May 20, 2028. Read SEC document |
| May 20, 2025 Filed May 21, 2025 20:57 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 28,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000033 · wk-form4_1747861034.xml · derivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,350 Underlying: Common Stock · 28,350 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 28,350 restricted stock units is as follows: 9,450 shares will vest on May 20, 2026; 9,450 shares will vest on May 20, 2027; 9,450 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 28,350 restricted stock units is as follows: 9,450 shares will vest on May 20, 2026; 9,450 shares will vest on May 20, 2027; 9,450 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 28,350 restricted stock units is as follows: 9,450 shares will vest on May 20, 2026; 9,450 shares will vest on May 20, 2027; 9,450 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000031 · wk-form4_1747426117.xml · derivative · entry 3 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,385 Underlying: Common Stock · 2,385 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units is as follows: 2,386 shares vested on May 15, 2024; 2,385 shares vested on May 15, 2025; and 2,385 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units is as follows: 2,386 shares vested on May 15, 2024; 2,385 shares vested on May 15, 2025; and 2,385 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units is as follows: 2,386 shares vested on May 15, 2024; 2,385 shares vested on May 15, 2025; and 2,385 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 680 | $1.95 | $1,326.00 |
DisclosureSEC source: 0001055726-25-000031 · wk-form4_1747426117.xml · nonDerivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,934 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,385 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000031 · wk-form4_1747426117.xml · nonDerivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units is as follows: 2,386 shares vested on May 15, 2024; 2,385 shares vested on May 15, 2025; and 2,385 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 34,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000004 · wk-form4_1740783943.xml · derivative · entry 4 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,650 Underlying: Common Stock · 34,650 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 34,650 restricted stock units granted on February 27, 2025 is as follows: 11,550 shares will vest on February 26, 2026; 11,550 shares will vest on February 26, 2027; 11,550 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 34,650 restricted stock units granted on February 27, 2025 is as follows: 11,550 shares will vest on February 26, 2026; 11,550 shares will vest on February 26, 2027; 11,550 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 34,650 restricted stock units granted on February 27, 2025 is as follows: 11,550 shares will vest on February 26, 2026; 11,550 shares will vest on February 26, 2027; 11,550 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 42,900 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001055726-25-000004 · wk-form4_1740783943.xml · derivative · entry 3 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,900 Underlying: Common Stock · 42,900 shares Expires 2035-02-27 F2 · derivative.exercise_date: The vesting schedule for the 42,900 options is as follows: 21,450 shares vested on February 27, 2025 and 21,450 shares will vest on February 26, 2026. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 5,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000004 · wk-form4_1740783943.xml · derivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,019 Underlying: Common Stock · 5,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 is as follows: 5,010 shares vested on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 is as follows: 5,010 shares vested on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 is as follows: 5,010 shares vested on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 5,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000004 · wk-form4_1740783943.xml · nonDerivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 is as follows: 5,010 shares vested on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 00:01 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 4,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000055 · wk-form4_1734566506.xml · derivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,292 Underlying: Common Stock · 4,292 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on March 31, 2026, subject to the reporting person's continuous service with the issuer through such date. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on March 31, 2026, subject to the reporting person's continuous service with the issuer through such date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on March 31, 2026, subject to the reporting person's continuous service with the issuer through such date. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 00:01 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 5,708 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001055726-24-000055 · wk-form4_1734566506.xml · derivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,708 Underlying: Common Stock · 5,708 shares Expires 2034-12-18 F1 · derivative.exercise_date: Options to vest 100% on March 31, 2026, subject to the reporting person's continuous service with the issuer through such date. Read SEC document |
| June 30, 2024 Filed Jul 1, 2024 21:02 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000042 · wk-form4_1719867738.xml · derivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,916 Underlying: Common Stock · 2,917 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 8,749 restricted stock units is as follows: 2,916 shares vested on June 30, 2023; 2,917 shares vested on June 30, 2024; and 2,916 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 8,749 restricted stock units is as follows: 2,916 shares vested on June 30, 2023; 2,917 shares vested on June 30, 2024; and 2,916 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 8,749 restricted stock units is as follows: 2,916 shares vested on June 30, 2023; 2,917 shares vested on June 30, 2024; and 2,916 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| June 30, 2024 Filed Jul 1, 2024 21:02 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,917 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000042 · wk-form4_1719867738.xml · nonDerivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 8,749 restricted stock units is as follows: 2,916 shares vested on June 30, 2023; 2,917 shares vested on June 30, 2024; and 2,916 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000029 · wk-form4_1715893577.xml · derivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,770 Underlying: Common Stock · 2,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units is as follows: 2,386 shares vested on May 15, 2024; 2,385 shares will vest on May 15, 2025; and 2,385 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units is as follows: 2,386 shares vested on May 15, 2024; 2,385 shares will vest on May 15, 2025; and 2,385 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units is as follows: 2,386 shares vested on May 15, 2024; 2,385 shares will vest on May 15, 2025; and 2,385 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,386 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000029 · wk-form4_1715893577.xml · nonDerivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units is as follows: 2,386 shares vested on May 15, 2024; 2,385 shares will vest on May 15, 2025; and 2,385 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 15,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000002 · wk-form4_1709157796.xml · derivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,029 Underlying: Common Stock · 15,029 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units is as follows: 5,010 shares will vest on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units is as follows: 5,010 shares will vest on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units is as follows: 5,010 shares will vest on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 18,750 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001055726-24-000002 · wk-form4_1709157796.xml · derivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2034-02-28 F1 · derivative.exercise_date: The vesting schedule for the 18,750 options is as follows: 4,688 shares vested on February 28, 2024; 4,688 shares will vest on February 28, 2025; 4,687 shares will vest on February 28, 2026; and 4,687 shares will vest on February 28, 2027. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 21:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000045 · wk-form4_1688418758.xml · derivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 105,000 restricted stock units is as follows: 35,000 shares vested on June 30, 2023; 35,000 shares will vest on June 30, 2024; 35,000 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 105,000 restricted stock units is as follows: 35,000 shares vested on June 30, 2023; 35,000 shares will vest on June 30, 2024; 35,000 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 105,000 restricted stock units is as follows: 35,000 shares vested on June 30, 2023; 35,000 shares will vest on June 30, 2024; 35,000 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 21:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 35,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000045 · wk-form4_1688418758.xml · nonDerivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 105,000 restricted stock units is as follows: 35,000 shares vested on June 30, 2023; 35,000 shares will vest on June 30, 2024; 35,000 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 85,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000043 · wk-form4_1684354347.xml · derivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,878 Underlying: Common Stock · 85,878 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 85,878 restricted stock units is as follows: 28,626 shares will vest on May 15, 2024; 28,626 shares will vest on May 15, 2025; and 28,626 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 85,878 restricted stock units is as follows: 28,626 shares will vest on May 15, 2024; 28,626 shares will vest on May 15, 2025; and 28,626 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 85,878 restricted stock units is as follows: 28,626 shares will vest on May 15, 2024; 28,626 shares will vest on May 15, 2025; and 28,626 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:38 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 112,500 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001055726-23-000003 · wf-form4_167762387214994.xml · derivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2033-02-27 F1 · derivative.exercise_date: The vesting schedule for the 112,500 options is as follows: 28,125 shares vested on February 27, 2023; 28,125 shares will vest on February 26, 2024; 28,125 shares will vest on February 26, 2025; and 28,125 shares will vest on February 26, 2026. Read SEC document |
| June 30, 2022 Filed Jul 6, 2022 22:21 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000044 · wf-form4_165714606951726.xml · derivative · entry 2 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 105,000 restricted stock units is as follows: 35,000 shares will vest on June 30, 2023; 35,000 shares will vest on June 30, 2024; 35,000 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 105,000 restricted stock units is as follows: 35,000 shares will vest on June 30, 2023; 35,000 shares will vest on June 30, 2024; 35,000 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 105,000 restricted stock units is as follows: 35,000 shares will vest on June 30, 2023; 35,000 shares will vest on June 30, 2024; 35,000 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 105,000 restricted stock units is as follows: 35,000 shares will vest on June 30, 2023; 35,000 shares will vest on June 30, 2024; 35,000 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| June 30, 2022 Filed Jul 6, 2022 22:21 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 160,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001055726-22-000044 · wf-form4_165714606951726.xml · derivative · entry 1 Sumner Michael John · CIK 0001936799 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2032-06-30 F1 · derivative.exercise_date: The vesting schedule for the 160,000 options is as follows: 40,000 shares vested on June 30, 2022; 40,000 shares will vest on June 30, 2023; 40,000 shares will vest on June 30, 2024; 40,000 shares will vest on June 30, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.